<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gemcitabine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gemcitabine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gemcitabine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8487" href="/d/html/8487.html" rel="external">see "Gemcitabine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10803" href="/d/html/10803.html" rel="external">see "Gemcitabine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F175343"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Infugem [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867026"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Gemcitabine [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1016262"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimetabolite (Pyrimidine Antagonist)</span></li></ul></div>
<div class="block dop drugH1Div" id="F10927324"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Details concerning dosing in combination regimens should also be consulted. Prolongation of the infusion time &gt;60 minutes and administration more frequently than once weekly have been shown to increase toxicity. Gemcitabine is associated with a low emetic potential risk; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23512831','lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23512831','lexi-content-ref-21465637'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97d7f73e-41cc-4d37-9e62-d167b26e9b8b">Germ cell tumor, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Germ cell tumor, refractory:</b> Limited data available: Adolescents ≥16 years: IV: 1,200 mg/m<sup>2</sup>/dose over 30 minutes on days 1, 8, and 15; repeat cycle every 28 days for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10080592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10080592'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ebbaa33-8ab0-44b8-a662-fd68c7d18267">Hodgkin lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed</b>
<b> or</b>
<b> refractory:</b> Limited data available; dosing regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gemcitabine in combination with brentuximab: </i>Children and Adolescents: IV: 1,000 mg/m<sup>2</sup>/dose over 100 minutes on days 1 and 8 (in combination with brentuximab); repeat cycle every 21 days; in the trial, the inclusion criteria had no minimum age and the youngest patient was 5 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30122620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30122620'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gemcitabine in combination with vinorelbine: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: IV: 1,000 mg/m<sup>2</sup>/dose over 100 minutes on days 1 and 8 (in combination with vinorelbine); repeat cycle every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19224841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19224841'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: IV: 1,000 mg/m<sup>2</sup>/dose over 60 minutes on days 1, 8, and 15 (in combination with vinorelbine); repeat cycle every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21072518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21072518'])">Ref</a></span>). Alternatively, 800 mg/m<sup>2</sup>/dose on days 1 and 4 (in combination with ifosfamide and vinorelbine); repeat cycle every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17229633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17229633'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5903c9f6-d536-451d-bba1-d8f53130fbeb">Sarcomas, refractory or relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcomas, refractory or relapsed (including Ewing sarcoma, osteosarcoma):</b> Limited data available: Children ≥3 years and Adolescents: IV: 675 <b>or</b> 1,000 mg/m<sup>2</sup>/dose over 90 minutes on days 1 and 8 (in combination with docetaxel); repeat cycle every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19727011','lexi-content-ref-18484657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19727011','lexi-content-ref-18484657'])">Ref</a></span>). Alternatively, 1,000 mg/m<sup>2</sup>/dose over 30 minutes on days 1 and 8 (in combination with oxaliplatin and irinotecan); repeat cycle every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21572345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21572345'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7177d86f-32ee-49d7-9ed7-ee88e7f0a1c0">Solid tumors, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, relapsed/refractory:</b> Limited data available: Children ≥1 year and Adolescents: IV: 1,000 mg/m<sup>2</sup>/dose over 30 minutes on days 1 and 8 (in combination with oxaliplatin and irinotecan); repeat cycle every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21572345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21572345'])">Ref</a></span>). Alternatively, 1,000 mg/m<sup>2</sup>/dose over 100 minutes on day 1 (in combination with oxaliplatin); repeat cycle every 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20943374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20943374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosage reductions for toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20943374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20943374'])">Ref</a></span>): 800 mg/m<sup>2</sup>/dose over 80 minutes if grade 3/4 nonhematological toxicity, grade 4 neutropenia with documented infection or lasting &gt;7 days, grade 3/4 thrombocytopenia lasting &gt;7 days or requiring platelets during &gt;7 days, or delay of next cycle ≥14 days; if necessary, dose could be reduced a second time to 600 mg/m<sup>2</sup>/dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Nonhematologic toxicity (all indications):</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">Hold or decrease gemcitabine dose by 50% for the following: Severe (grade 3 or 4) nonhematologic toxicity until resolved (excludes nausea, vomiting, or alopecia [no dose modifications recommended]).</p>
<p style="text-indent:-2em;margin-left:8em;">Permanently discontinue gemcitabine for any of the following: Unexplained dyspnea (or other evidence of severe pulmonary toxicity), severe hepatotoxicity, hemolytic uremic syndrome (HUS), capillary leak syndrome (CLS), posterior reversible encephalopathy syndrome (PRES).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Hematologic toxicity:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Breast cancer: </b></p>
<p style="text-indent:-2em;margin-left:10em;">Day 1:</p>
<p style="text-indent:-2em;margin-left:12em;">Absolute neutrophil count (ANC) ≥1,500/mm<sup>3</sup> and platelet count ≥100,000/mm<sup>3</sup>: Administer 100% of full dose.</p>
<p style="text-indent:-2em;margin-left:12em;">ANC &lt;1,500/mm<sup>3</sup> or platelet count &lt;100,000/mm<sup>3</sup>: Hold dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 8:</p>
<p style="text-indent:-2em;margin-left:12em;">ANC ≥1,200/mm<sup>3</sup> and platelet count &gt;75,000/mm<sup>3</sup>: Administer 100% of full dose.</p>
<p style="text-indent:-2em;margin-left:12em;">ANC 1,000 to 1,199/mm<sup>3</sup> or platelet count 50,000 to 75,000/mm<sup>3</sup>: Administer 75% of full dose.</p>
<p style="text-indent:-2em;margin-left:12em;">ANC 700 to 999/mm<sup>3</sup> and platelet count ≥50,000/mm<sup>3</sup>: Administer 50% of full dose.</p>
<p style="text-indent:-2em;margin-left:12em;">ANC &lt;700/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>: Hold dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Non-small cell lung cancer (cisplatin dosage may also require adjustment): </b></p>
<p style="text-indent:-2em;margin-left:10em;">ANC ≥1,000/mm<sup>3</sup> and platelet count ≥100,000/mm<sup>3</sup>: Administer 100% of full dose.</p>
<p style="text-indent:-2em;margin-left:10em;">ANC 500 to 999/mm<sup>3</sup> or platelet count 50,000 to 99,999/mm<sup>3</sup>: Administer 75% of full dose.</p>
<p style="text-indent:-2em;margin-left:10em;">ANC &lt;500/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>: Hold dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Ovarian cancer:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Day 1:</p>
<p style="text-indent:-2em;margin-left:12em;">ANC ≥1,500/mm<sup>3</sup> and platelet count ≥100,000/mm<sup>3</sup>: Administer 100% of full dose.</p>
<p style="text-indent:-2em;margin-left:12em;">ANC &lt;1,500/mm<sup>3</sup> or platelet count &lt;100,000/mm<sup>3</sup>: Delay treatment cycle.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 8:</p>
<p style="text-indent:-2em;margin-left:12em;">ANC ≥1,500/mm<sup>3</sup> and platelet count ≥100,000/mm<sup>3</sup>: Administer 100% of full dose.</p>
<p style="text-indent:-2em;margin-left:12em;">ANC 1,000 to 1,499/mm<sup>3</sup> or platelet count 75,000 to 99,999/mm<sup>3</sup>: Administer 50% of full dose.</p>
<p style="text-indent:-2em;margin-left:12em;">ANC &lt;1,000/mm<sup>3</sup> or platelet count &lt;75,000/mm<sup>3</sup>: Hold dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Hematologic toxicity in previous cycle (dosing adjustment for subsequent cycles):</p>
<p style="text-indent:-2em;margin-left:12em;">Initial occurrence: ANC &lt;500/mm<sup>3</sup> for &gt;5 days, ANC &lt;100/mm<sup>3</sup> for &gt;3 days, febrile neutropenia, platelet count &lt;25,000/mm<sup>3</sup>, or cycle delay &gt;1 week due to toxicity: Permanently reduce gemcitabine to 800 mg/m<sup>2</sup> on days 1 and 8.</p>
<p style="text-indent:-2em;margin-left:12em;">Subsequent occurrence: ANC &lt;500/mm<sup>3</sup> for &gt;5 days, ANC &lt;100/mm<sup>3</sup> for &gt;3 days, neutropenic fever, platelet count &lt;25,000/mm<sup>3</sup>, or cycle delay &gt;1 week due to toxicity: Permanently reduce gemcitabine to 800 mg/m<sup>2</sup> and administer on day 1 only.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Pancreatic cancer: </b></p>
<p style="text-indent:-2em;margin-left:10em;">ANC ≥1,000/mm<sup>3</sup> and platelet count ≥100,000/mm<sup>3</sup>: Administer 100% of full dose.</p>
<p style="text-indent:-2em;margin-left:10em;">ANC 500 to 999/mm<sup>3</sup> or platelet count 50,000 to 99,999/mm<sup>3</sup>: Administer 75% of full dose.</p>
<p style="text-indent:-2em;margin-left:10em;">ANC &lt;500/mm<sup>3</sup> or platelet count &lt;50,000/mm<sup>3</sup>: Hold dose.</p></div>
<div class="block dorp drugH1Div" id="F51112464"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; based on experience in adult patients, discontinue if severe kidney impairment or hemolytic uremic syndrome (HUS) occurs during gemcitabine treatment.</p></div>
<div class="block dohp drugH1Div" id="F51112465"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Based on experience in adult patients, discontinue if severe hepatotoxicity occurs during treatment with gemcitabine.</p></div>
<div class="block doa drugH1Div" id="F175347"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8487" href="/d/html/8487.html" rel="external">see "Gemcitabine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prolongation of the infusion duration &gt;60 minutes and administration more frequently than once weekly have been shown to increase toxicity. If using premixed infusion bags, select the premixed bag(s) that allows for a variance of ≤5% of the BSA-based calculated dose; do not use premixed infusions bags for patients requiring a bag size of &lt;1,200 mg/dose (select a different formulation).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fdc525d-5f7d-4513-9933-4cf238a80bef">Biliary tract cancer, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, adjuvant therapy (off-label use):</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle (in combination with capecitabine) for 4 cycles, followed by capecitabine in combination with concurrent radiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25964250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25964250'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70eab7a6-b58d-487c-8f61-229bd7e67a11">Biliary tract cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, advanced (off-label use):</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8 of a 21-day cycle (in combination with cisplatin) until disease progression or unacceptable toxicity or a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20375404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20375404'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8 of a 21-day cycle (in combination with capecitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15800324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15800324'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> infused at 10 mg/m<sup>2</sup>/minute every 2 weeks (in combination with oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15319238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15319238'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle (in combination with durvalumab and cisplatin) for up to 8 cycles, followed by durvalumab as a single agent until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Oh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Oh.1'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle (in combination with cisplatin [maximum 8 cycles] and pembrolizumab [maximum 35 cycles]) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37075781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37075781'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3810c766-bd22-4b38-a74f-83d570ec742e">Bladder cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic:</i>
<b>IV:</b> 1,000 mg/m<sup>2</sup> over 30 to 60 minutes days 1, 8, and 15; repeat cycle every 28 days (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11001674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11001674'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22162575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22162575'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes on days 1 and 8 every 21 days (in combination with paclitaxel and cisplatin [PCG regimen]; refer to protocol for administration sequence details) for up to 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22370319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22370319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transitional cell carcinoma (refractory):</i>
<b>Intravesicular instillation:</b> 2,000 mg (in 100 mL NS; retain for 1 hour) twice weekly for 3 weeks; repeat cycle every 4 weeks for at least 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16782913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16782913'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8423721-7a23-4fed-bf36-91a0c75f98e6">Breast cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic:</b>
<b>IV:</b> 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with paclitaxel) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18711184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18711184'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing/combinations:</i>
<b>IV: </b>800 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 of a 28-day treatment cycle (as a single agent) until disease progression or unacceptable toxicity; dose could be increased if the first cycle was tolerated; refer to protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7595731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7595731'])">Ref</a></span>) <b>or </b>1,000 mg/m<sup>2</sup> on days 1 and 8 every 3 weeks (in combination with carboplatin and pembrolizumab for triple-negative breast cancer); refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33278935','lexi-content-ref-35857659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33278935','lexi-content-ref-35857659'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b40337c-ce5a-45e3-a7ae-4d056ec67c06">Cervical cancer, recurrent or persistent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer, recurrent or persistent (off-label use):</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup> days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19720909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19720909'])">Ref</a></span>) <b>or</b> 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10620443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10620443'])">Ref</a></span>) <b>or</b> 800 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15; repeat cycle every 28 days (as a single-agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15589587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15589587'])">Ref</a></span>) <b>or</b> 800 mg/m<sup>2</sup> days 1 and 8; repeat cycle every 28 days (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16271750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16271750'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="122140f0-6b4e-4478-acb7-39e18f3cf86b">Head and neck cancer: nasopharyngeal, locally advanced, advanced, or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer: nasopharyngeal, locally advanced, advanced, or metastatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced disease: Gemcitabine/cisplatin induction chemotherapy:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle (in combination with cisplatin) for 3 cycles followed by chemoradiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31150573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31150573'])">Ref</a></span>). A minimum of 2 cycles is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33405943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33405943'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy for N2-3 disease: </i>
<b>IV: </b>1,000 mg/m<sup>2</sup> on days 1 and 8 every 3 weeks (in combination with cisplatin) for 3 cycles following concurrent chemoradiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37290468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37290468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Metastatic or recurrent, locally advanced (first-line treatment):</i>
<b>IV:</b> 1,000 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle (in combination with cisplatin and toripalimab) until disease progression or unacceptable toxicity for up to a maximum of 6 combination cycles (whichever occurred first); followed by single-agent toripalimab until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34341578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34341578'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17909810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17909810'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days (in combination with vinorelbine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22748450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22748450'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f081df1a-9b00-48a6-9824-66a3795ca4c4">Hodgkin lymphoma, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed (off-label use):</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup> (800 mg/m<sup>2</sup> if post-transplant) over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with vinorelbine and doxorubicin liposomal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17426059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17426059'])">Ref</a></span>) <b>or</b> 800 mg/m<sup>2</sup> days 1 and 4; repeat cycle every 21 days (in combination with ifosfamide, mesna, vinorelbine, and prednisolone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17229633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17229633'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b00a027-bd66-4d8a-903c-6d47086c0533">Malignant pleural mesothelioma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma (off-label use):</b>
<b>IV:</b> 1,250 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (as a single agent) for up to 10 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10375105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10375105'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8 and 15 every 28 days (in combination with cisplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12189542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12189542'])">Ref</a></span>) <b>or</b> 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days (in combination with cisplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11875695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11875695'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="860b407c-d865-471b-956d-1dff47da5763">Non-Hodgkin lymphoma, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma, refractory (off-label use):</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin and dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15386331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15386331'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> every 15 to 21 days (in combination with oxaliplatin and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18005385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18005385'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c3733a8-739b-413d-9142-a3e8659be912">Non–small cell lung cancer, inoperable, locally advanced, or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, inoperable, locally advanced, or metastatic: IV:</b> 1,000 mg/m<sup>2</sup> over 30 minutes on days 1, 8, and 15; repeat cycle every 28 days (in combination with cisplatin) for a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10623702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10623702'])">Ref</a></span>) <b>or</b> 1,250 mg/m<sup>2</sup> over 30 minutes on days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) for a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10458212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10458212'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-small cell lung cancer off-label dosing/combinations: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with durvalumab, tremelimumab, and a platinum (squamous histology): </i>
<b>IV:</b> 1,000 or 1,250 mg/m<sup>2</sup> on days 1 and 8 every 21 days (in combination with either cisplatin or carboplatin, and durvalumab and tremelimumab) for 4 cycles, followed by tremelimumab (for 1 additional dose) and durvalumab; continue durvalumab until disease progression or unacceptable toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with carboplatin:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> over 30 minutes on days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19433683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19433683'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes on days 1, 8, and 15; repeat cycle every 28 days (in combination with carboplatin) for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12879472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12879472'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with docetaxel:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> over 30 minutes on days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15741225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15741225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with vinorelbine:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> on days 1, 8, and 15; repeat cycle every 28 days (in combination with vinorelbine) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17922972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17922972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with nivolumab and cisplatin (neoadjuvant </i>
<i>therapy):</i>
<b>IV: </b>1,000 or 1,250 mg/m<sup>2</sup> on days 1 and 8 every 3 weeks (in combination with nivolumab and cisplatin) for up to 3 cycles; refer to protocol for further information, including histology details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35403841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35403841'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ca88c47-fed2-4025-88d5-3331e749f45f">Ovarian cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced: IV:</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15839957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15839957'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing (as a single agent): </i>
<b>IV: </b>1,000 mg/m<sup>2</sup> over 30 to 60 minutes days 1 and 8; repeat cycle every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17602086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17602086'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ccef4479-b48f-40bb-a0b8-4d5b64d7eb76">Pancreatic cancer, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, locally advanced or metastatic:</b>
<b>IV:</b> Initial: 1,000 mg/m<sup>2</sup> over 30 minutes once weekly for 7 weeks followed by 1 week rest; then administer on days 1, 8, and 15 every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9196156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9196156'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing/combinations: </i>
<b>IV: </b>1,000 mg/m<sup>2</sup> days 1, 8, and 15 every 28 days (in combination with paclitaxel [protein bound]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24131140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24131140'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (in combination with capecitabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19858379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19858379'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes weekly for up to 7 weeks followed by 1 week rest; then weekly for 3 weeks out of every 4 weeks (in combination with erlotinib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17452677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17452677'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 15 every 28 days (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16921047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16921047'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> infused at 10 mg/m<sup>2</sup>/minute every 14 days (in combination with oxaliplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15908661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15908661'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a39e464-8bb6-4795-a1b3-a3b1646f0ac0">Pancreatic cancer, potentially curable, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, potentially curable, adjuvant therapy (off-label use; alternative therapy):</b>
<b>Note:</b> American Society of Clinical Oncology guidelines for potentially curable pancreatic cancer recommend 6 months of adjuvant therapy if recovery is complete; while first-line therapy with another regimen is preferred, the gemcitabine/capecitabine regimen or single-agent gemcitabine therapy are options if toxicity/tolerance are concerns with the preferred regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination regimen:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> on days 1, 8, and 15 every 28 days (in combination with capecitabine) for 6 cycles beginning within 12 weeks of resection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28129987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28129987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> on days 1, 8, and 15 every 28 days for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24104372','lexi-content-ref-17227978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24104372','lexi-content-ref-17227978'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2478182-746a-4e3d-a171-3437dfb7f157">Renal carcinoma, non-clear cell, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal carcinoma, non-clear cell, metastatic (off-label use): IV:</b> 1,250 mg/m<sup>2</sup> over 30 minutes on days 1 and 8 every 21 days (in combination with either cisplatin or carboplatin) or until disease progression or unacceptable toxicity for up to a maximum of 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17437788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17437788'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbb6f1a7-0651-4365-8e89-a7d3245972cd">Sarcomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcomas (off-label uses):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ewing sarcoma, refractory:</i>
<b>IV: </b>675 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18484657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18484657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Osteosarcoma, refractory:</i>
<b>IV: </b>675 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18484657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18484657'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> weekly for 7 weeks followed by 1 week rest; then weekly for 3 weeks out of every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10663634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10663634'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Soft tissue sarcoma, advanced:</i>
<b>IV: </b>800 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with vinorelbine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17385194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17385194'])">Ref</a></span>) <b>or</b> 675 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15117993']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15117993'])">Ref</a></span>) <b>or</b> 900 mg/m<sup>2</sup> over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17602081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17602081'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6379e00-1d0d-4a31-8fd9-f9acd15e1849">Small cell lung cancer, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, relapsed/refractory (off-label use):</b>
<b>IV:</b> 1,000 to 1,250 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (as a single agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12697880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12697880'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a6f21b9-dea7-49c7-b936-557549074c7f">Testicular cancer, refractory germ cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer, refractory germ cell (off-label use): IV:</b> 1,000 to 1,250 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days (in combination with oxaliplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16757095','lexi-content-ref-14701772','lexi-content-ref-14998855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16757095','lexi-content-ref-14701772','lexi-content-ref-14998855'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days for up to 6 cycles (in combination with paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11919245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11919245'])">Ref</a></span>) <b>or</b> 800 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days (in combination with oxaliplatin and paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18006893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18006893'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c21d4f7-c73b-416e-8ef1-a9549a182e99">Thymic malignancies, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Thymic malignancies, refractory (off-label use): IV: </b>1,000 mg/m<sup>2</sup> on days 1 and 8 every 21 days (in combination with capecitabine) until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25471029','lexi-content-ref-19880439']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25471029','lexi-content-ref-19880439'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6487b19-e21f-456e-a849-5f5a5f2ee85f">Unknown primary carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary carcinoma (off-label use):</b>
<b>IV:</b> 1,250 mg/m<sup>2</sup> days 1 and 8 every 21 days (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12972523','lexi-content-ref-22317952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12972523','lexi-content-ref-22317952'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1 and 8 every 21 days for up to 6 cycles (in combination with docetaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15022294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15022294'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> on days 1 and 8 every 21 days (in combination with irinotecan) for 4 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20164695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20164695'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f9672781-bc35-4a58-905d-1d3589a2e99c">Uterine sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uterine sarcoma (off-label use):</b>
<b>IV:</b> 900 mg/m<sup>2</sup> over 90 minutes days 1 and 8 every 21 days (in combination with docetaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18394689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18394689'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> over 30 minutes days 1, 8, and 15 every 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14766260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14766260'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990810"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:0em;">
<i>
<b>Dosage adjustment prior to treatment initiation:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: <b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494637','lexi-content-ref-15170150','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-10894879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494637','lexi-content-ref-15170150','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-10894879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: <b>IV:</b> No dosage adjustment necessary. However, risk of hematologic toxicity may be increased in these patients, which may require gemcitabine dose modification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494637','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-16162979','lexi-content-ref-22936563','lexi-content-ref-10894879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494637','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-16162979','lexi-content-ref-22936563','lexi-content-ref-10894879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Gemcitabine is metabolized intracellularly and then converted to dFdU; dFdU is dialyzable (~50% removal by single session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12655447','lexi-content-ref-19726456','lexi-content-ref-18270381']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12655447','lexi-content-ref-19726456','lexi-content-ref-18270381'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-31186983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-31186983'])">Ref</a></span>). Consider performing hemodialysis 6 to 12 hours after completing the gemcitabine infusion to limit the potential toxic effects of dFdU accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29578402','lexi-content-ref-20118214','lexi-content-ref-31186983','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29578402','lexi-content-ref-20118214','lexi-content-ref-31186983','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Risk of hematologic toxicity may be increased in patients with severe kidney impairment, which may require gemcitabine dose modification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494637','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-16162979','lexi-content-ref-22936563','lexi-content-ref-10894879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494637','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-16162979','lexi-content-ref-22936563','lexi-content-ref-10894879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Extent of dialyzability unknown:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29578402','lexi-content-ref-20118214','lexi-content-ref-31186983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29578402','lexi-content-ref-20118214','lexi-content-ref-31186983'])">Ref</a></span>). Risk of hematologic toxicity may be increased in patients with severe kidney impairment, which may require gemcitabine dose modification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494637','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-16162979','lexi-content-ref-22936563','lexi-content-ref-10894879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494637','lexi-content-ref-17309673','lexi-content-ref-17222747','lexi-content-ref-16162979','lexi-content-ref-22936563','lexi-content-ref-10894879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, myelosuppression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, myelosuppression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> No dosage adjustment necessary (expert opinion). Consider performing PIRRT 6 to 12 hours after completing the gemcitabine infusion to limit the potential toxic effects of dFdU accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage adjustment for renal toxicity during treatment:</b></i>Discontinue if severe renal toxicity or hemolytic uremic syndrome occur during gemcitabine treatment.</p></div>
<div class="block doha drugH1Div" id="F50988014"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Dosage adjustment for hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:0em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling. The following adjustments have been reported:</p>
<p style="text-indent:-2em;margin-left:6em;">Transaminases elevated (with normal bilirubin or total bilirubin &lt;1.6 mg/dL): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181','lexi-content-ref-10894879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181','lexi-content-ref-10894879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin &gt;1.6 mg/dL: Use initial dose of 800 mg/m<sup>2</sup>; may escalate if tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-10894879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-10894879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Total bilirubin ≥1.6 mg/dL: May begin with 80% of the usual gemcitabine dose and increase the dose if tolerated or may consider initiating with full dose and careful active monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for hepatotoxicity during treatment:</b> Discontinue if severe hepatotoxicity occurs during gemcitabine treatment.</p></div>
<div class="block adr drugH1Div" id="F175312"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency of adverse reactions reported for single-agent use of gemcitabine only.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (20%), edema (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Drowsiness (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (30%), alopecia (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (69%), diarrhea (19%), stomatitis (11%; grade 3: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (45%), hematuria (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (68%; grade 3: 7%; grade 4: 1%), neutropenia (63%; grade 3: 19%; grade 4: 6%), thrombocytopenia (24%; grade 3: 4%; grade 4: 1%), hemorrhage (17%; grade 3: &lt;1%; grade 4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (68%), increased serum aspartate aminotransferase (67%), increased serum alkaline phosphatase (55%), hyperbilirubinemia (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (23%), flu-like symptoms (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (41%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Paresthesia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports (reported with single-agent use or with combination therapy): Acute myocardial infarction, acute respiratory distress syndrome, bullous skin disease, capillary leak syndrome, cardiac arrhythmia, cardiac failure, cellulitis (including pseudocellulitis), cerebrovascular accident (Kuenen 2002), desquamation, eosinophilic pneumonitis, gangrene of skin and/or subcutaneous tissues, hemolytic-uremic syndrome, hepatic failure, hepatic sinusoidal obstruction syndrome, hepatotoxicity, interstitial pneumonitis, petechia (Nishijima 2013; Zupancic 2007), pruritus (Curtis 2016), pulmonary edema, pulmonary fibrosis, radiation recall phenomenon, renal failure syndrome, respiratory failure, reversible posterior leukoencephalopathy syndrome, sepsis, severe dermatological reaction, supraventricular cardiac arrhythmia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura (Nishijima 2013; Zupancic 2007), vasculitis (peripheral)</p></div>
<div class="block coi drugH1Div" id="F175327"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to gemcitabine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F175309"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: May cause bone marrow suppression (neutropenia, thrombocytopenia, and anemia), including grade 3 or 4 hematologic toxicity. Myelosuppression is generally the dose-limiting toxicity and is increased when used in combination with other chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Capillary leak syndrome: Capillary leak syndrome with serious consequences has been reported, both with single-agent gemcitabine and with combination chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic uremic syndrome: Hemolytic uremic syndrome (HUS) has been reported; may lead to renal failure and dialysis (including fatalities). Most fatal cases of renal failure were due to HUS. Thrombotic microangiopathy other than HUS has also been reported. Assess for HUS in patients who develop anemia with microangiopathic hemolysis, elevation of bilirubin or lactate dehydrogenase, reticulocytosis, severe thrombocytopenia, and/or renal failure (increased serum creatinine or BUN). Renal failure may not be reversible despite gemcitabine discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious hepatotoxicity (including liver failure and death) has been reported with gemcitabine (when used alone or with other potentially hepatotoxic medications). The use of gemcitabine in patients with hepatic impairment (history of cirrhosis, hepatitis, or alcoholism) or in patients with hepatic metastases may lead to exacerbation of hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylaxis and allergic reactions (including bronchospasm and anaphylactoid reactions) have been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Posterior reversible encephalopathy syndrome: Posterior reversible encephalopathy syndrome (PRES) has been reported, both with single-agent therapy and with combination chemotherapy. PRES may manifest with blindness, confusion, headache, hypertension, lethargy, seizure, and other visual and neurologic disturbances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Pulmonary toxicity, including adult respiratory distress syndrome, interstitial pneumonitis, pulmonary edema, and pulmonary fibrosis, has been observed; may lead to respiratory failure (some fatal) despite gemcitabine discontinuation. The onset of pulmonary toxicity symptoms may be delayed up to 2 weeks beyond the last gemcitabine dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: In some studies, higher rates of grades 3 and 4 neutropenia and thrombocytopenia have been observed in patients ≥65 years of age (compared to patients &lt;65 years of age).</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation therapy recipients: Gemcitabine is not recommended for use in combination with radiation therapy; radiation toxicity, including tissue injury, severe mucositis, esophagitis, or pneumonitis, has been reported with concurrent and nonconcurrent administration. Gemcitabine has radiosensitizing activity when gemcitabine and radiation therapy are given together or ≤7 days apart. Radiation recall may occur when gemcitabine and radiation therapy are given &gt;7 days apart.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion duration/frequency: Prolongation of the infusion duration &gt;60 minutes or more frequent than weekly dosing have been shown to alter the half-life and increase toxicity (hypotension, flu-like symptoms, myelosuppression, weakness). A fixed-dose rate (FDR) infusion rate of 10 mg/m<sup>2</sup>/minute has been studied in adults in order to optimize the pharmacokinetics (off-label); prolonged infusion times increase the intracellular accumulation of the active metabolite, gemcitabine triphosphate (Ko 2006; Tempero 2003). Patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (Ko 2006; Poplin 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple concentrations: Gemcitabine is available in multiple formulations and concentrations; verify product and concentration prior to admixture to assure appropriate dose preparation.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F55159755"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F175320"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/5.26 mL (5.26 mL); 200 mg/2 mL (2 mL); 1 g/10 mL (10 mL); 1 g/26.3 mL (26.3 mL); 1.5 g/15 mL (15 mL); 2 g/20 mL (20 mL); 2 g/52.6 mL (52.6 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/5.26 mL (5.26 mL); 1 g/26.3 mL (26.3 mL); 2 g/52.6 mL (52.6 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infugem: gemcitabine hydrochloride 1,200 mg/120 mL in NaCl 0.9% (120 mL [DSC]); gemcitabine hydrochloride 2,200 mg/220 mL in NaCl 0.9% (220 mL [DSC]); gemcitabine hydrochloride 2,000 mg/200 mL in NaCl 0.9% (200 mL [DSC]); gemcitabine hydrochloride 1,300 mg/130 mL in NaCl 0.9% (130 mL [DSC]); gemcitabine hydrochloride 1,400 mg/140 mL in NaCl 0.9% (140 mL [DSC]); gemcitabine hydrochloride 1,500 mg/150 mL in NaCl 0.9% (150 mL [DSC]); gemcitabine hydrochloride 1,600 mg/160 mL in NaCl 0.9% (160 mL [DSC]); gemcitabine hydrochloride 1,700 mg/170 mL in NaCl 0.9% (170 mL [DSC]); gemcitabine hydrochloride 1,800 mg/180 mL in NaCl 0.9% (180 mL [DSC]) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infugem: gemcitabine hydrochloride 1,900 mg/190 mL in NaCl 0.9% (190 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg (1 ea); 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg (1 ea); 1 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F175305"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524622"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gemcitabine HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $7.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/26.3 mL (per mL): $1.00 - $2.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 g/15 mL (per mL): $6.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/20 mL (per mL): $7.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/52.6 mL (per mL): $1.02 - $2.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/2 mL (per mL): $26.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5.26 mL (per mL): $1.14 - $2.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Gemcitabine HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $50.26 - $800.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $128.00 - $154.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $9.29 - $48.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867027"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 38 mg/mL (5.3 mL, 26.3 mL, 52.6 mL); 40 mg/mL (5 mL, 25 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg ([DSC]); 1 g (1 ea); 2 g (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612904"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Per manufacturer: Infuse over 30 minutes; if utilizing premixed infusion bags and 2 premixed bags are required, infuse the total volume of both bags over 30 minutes; however, for other protocols and uses, infusion times may vary (refer to specific protocols). <b>Note:</b> Prolongation of the infusion time &gt;60 minutes has been shown to prolong gemcitabine's half-life and increase toxicity in adults; gemcitabine has been administered in adults utilizing a fixed-dose rate (FDR) of 10 mg/m<sup>2</sup>/minute to optimize the pharmacokinetics; prolonged infusion times increase the intracellular accumulation of the active metabolite, gemcitabine triphosphate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16344320','lexi-content-ref-12885837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16344320','lexi-content-ref-12885837'])">Ref</a></span>); patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16344320','lexi-content-ref-19581537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16344320','lexi-content-ref-19581537'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F175324"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For labeled indications, infuse over 30 minutes; if utilizing premixed infusion bags and 2 premixed bags are required, infuse the total volume of both bags over 30 minutes (follow manufacturer’s instructions to spike premixed bag and add administration set).</p>
<p style="text-indent:-2em;margin-left:4em;">For off-label uses, infusion times may vary (refer to specific references). <b>Note:</b> Prolongation of the infusion time &gt;60 minutes has been shown to increase toxicity. Gemcitabine has been administered at a fixed-dose rate (FDR) infusion rate of 10 mg/m<sup>2</sup>/minute to optimize the pharmacokinetics (off-label); prolonged infusion times increase the intracellular accumulation of the active metabolite, gemcitabine triphosphate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16344320','lexi-content-ref-12885837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16344320','lexi-content-ref-12885837'])">Ref</a></span>). Patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16344320','lexi-content-ref-19581537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16344320','lexi-content-ref-19581537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Bladder cancer (transitional cell; off-label use): For intravesicular (bladder) instillation (off-label route), gemcitabine was diluted in 50 to 100 mL normal saline; patients were instructed to retain in the bladder for 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19841330','lexi-content-ref-16782913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19841330','lexi-content-ref-16782913'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132601"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F175336"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Lyophilized powder: Store intact vials at room temperature of 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Reconstituted vials are stable for 24 hours at room temperature (discard if not used within 24 hours of reconstitution). Do not refrigerate (may form crystals).</p>
<p style="text-indent:-2em;margin-left:2em;">Concentrated solution for injection (vials): Varies by manufacturer; refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Premixed infusion solutions: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze (may result in crystallization).</p>
<p style="text-indent:-2em;margin-left:2em;">Solutions prepared/diluted for infusion in NS are stable for 24 hours at room temperature. Do not refrigerate (may result in crystallization).</p></div>
<div class="block usep drugH1Div" id="F53567059"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of locally advanced, inoperable (stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer (NSCLC), metastatic breast cancer, and advanced relapsed ovarian cancer as part of combination therapy (FDA approved in adults); treatment of locally advanced or metastatic pancreatic cancer as a single agent (FDA approved in adults); has also been used in the treatment of refractory solid tumors (including brain tumors), refractory or relapsed sarcomas (including Ewing sarcoma, osteosarcoma), refractory or relapsed Hodgkin lymphoma, and refractory germ cell tumors.</p></div>
<div class="block mst drugH1Div" id="F175393"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gemcitabine may be confused with gemtuzumab ozogamicin</p>
<p style="text-indent:-2em;margin-left:4em;">Gemzar may be confused with Zinecard</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Multiple concentrations: Gemcitabine is available in multiple formulations and concentrations; verify product and concentration prior to admixture to assure appropriate dose preparation.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299393"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F175314"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bleomycin: Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cedazuridine: May increase the serum concentration of Cytidine Deaminase Substrates.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil (Systemic): Gemcitabine may increase the serum concentration of Fluorouracil (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): May enhance the adverse/toxic effect of Gemcitabine. Specifically, the risk for thrombotic microangiopathy may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Gemcitabine may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52111795"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status (with pregnancy test) prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 6 months after the final gemcitabine dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months after the final gemcitabine dose.</p></div>
<div class="block pri drugH1Div" id="F175329"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and on findings from animal reproduction studies, in utero exposure to gemcitabine may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of gemcitabine in pregnancy is limited (Lubner 2011; Wiesweg 2014).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53567060"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelet count (prior to each dose); LFTs (baseline and periodically), renal function (serum creatinine and BUN; prior to initiation of therapy and periodically, thereafter); monitor electrolytes, including potassium, magnesium, and calcium (when in combination therapy with cisplatin). Evaluate pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor pulmonary function. Monitor for signs/symptoms of capillary leak syndrome, hemolytic uremic syndrome (HUS; assess for HUS if anemia with microangiopathic hemolysis, elevation of bilirubin or lactate dehydrogenase, reticulocytosis, severe thrombocytopenia, and/or renal failure [increased serum creatinine or BUN] develops), hepatotoxicity, hypersensitivity, posterior reversible encephalopathy syndrome (confirm diagnosis with MRI), and pulmonary toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F175308"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase, cell cycle-specific for the S-phase of the cycle (also blocks cellular progression at G1/S-phase). Gemcitabine is phosphorylated intracellularly by deoxycytidine kinase to gemcitabine monophosphate, which is further phosphorylated to active metabolites gemcitabine diphosphate and gemcitabine triphosphate. Gemcitabine diphosphate inhibits DNA synthesis by inhibiting ribonucleotide reductase; gemcitabine triphosphate incorporates into DNA and inhibits DNA polymerase.</p></div>
<div class="block phk drugH1Div" id="F175326"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed into tissues; present in ascitic fluid; V<sub>d</sub>: Infusions &lt;70 minutes: 50 L/m<sup>2</sup>; Long infusion times (70 to 285 minutes): 370 L/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Negligible</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleoside metabolites; the metabolites are then converted to inactive uracil metabolite (dFdU).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Gemcitabine: Infusion time ≤70 minutes: 42 to 94 minutes; infusion time 3 to 4 hours: 4 to 10.5 hours (affected by age and gender)</p>
<p style="text-indent:-2em;margin-left:4em;">Metabolite (gemcitabine triphosphate), terminal phase: 1.7 to 19.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 30 minutes after completion of infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (92% to 98%; primarily as inactive uracil metabolite [dFdU]); feces (&lt;1%)</p></div>
<div class="block phksp drugH1Div" id="F51196101"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The lower clearance in geriatric patients results in higher concentrations of gemcitabine for any given dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Gemcitabine clearance is lower and the half-life is longer in females (compared with males).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F175330"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Gembio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Gemalata | Gemcitabin | Gemcitabin Accord | Gemcitabin ebewe | Gemcitabin hospira | Gemcitabin Stada | Gemsol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dbl gemcitabine | Gemcitabine | Gemcitabine as | Gemcitabine ebewe</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine Mylan | Gemcitabine Teva | Gemsol</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Gemtero</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Gembin | Gemcitabine accord | Gemcitabine actavis | Gemcitabine hospira | Gemsol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de gencitabina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin Accord | Gemcitabin fresenius | Gemcitabin sandoz | Gemcitabin teva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Gembin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabina | Genuten</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Yu jie | Ze fei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Gebitan | Gemcitabina | Virulizin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin Accord | Gemcitabin ebewe | Gemcitabin teva | Gemcitabine hospira | Gemcitabine kabi | Gemstad | Gemzar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ebegemci | Gemci Cell | Gemcitabin Accord | Gemcitabin actavis | Gemcitabin Hexal | Gemcitabin hikma | Gemcitabin hospira | Gemcitabin NC | Gemcitabin Onkovis | Gemcitabin teva | Gemsol NC | Ribozar</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Gensitax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine ebewe | Gemcitabine kabi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Eupizar | Gemazar | Gemcitabine | Gemzar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabina Accord | Gemcitabina actavis | Gemcitabina fresenius | Gemcitabina Hospira | Gemcitabina prasfarma | Gemcitabina Stada</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin hospira | Gemcitabin sun | Gemcitabine accord</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine actavis | Gemcitabine arrow | Gemcitabine Intas | Gemcitabine sandoz | Gemcitabine sun | Gemcitabine Teva | Gemzar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine accord | Gemnil | Medigem</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin ebewe</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin hospira | Gemcitabin sandoz | Gemzar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin teva | Gemcitabine accord | Gemcitabine ebewe | Gitrabin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine ebewe | Kabigeta</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Gemzar</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Stricyte</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gembin | Gemcitabina | Gemcitabina Accord | Gemcitabina aurobindo | Gemcitabina Hospira | Gemcitabina sun | Gemsol | Solgekma</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine sandoz</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Gemcirex | Gemita | Gemzar</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Crabcitabin | Gemcitabine | Gemtan | Geroam | Pfizer gemcitabine | Syg gemcitabine hcl | Zeroam</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Gemci Cell | Gemzar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gembin | Gemcitabine hospira | Gemcitabine kabi | Gemcitabine Stada | Gemsol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Gembin | Gemcitabine hospira | Gemcitabine kabi | Gemsol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Celge | Kavya | Lenfitabin | Topeteno</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Gemita rtu</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Gembin | Gemcitabine sandoz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine | Gemcitabine Hikma | Gemcitabine sun</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin | Gemcitabin Accord | Gemcitabin actavis | Gemcitabin sandoz | Gemkabi</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Gemzar | Zefei</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Biogem | Gemcitabel | Zefei</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gembin | Gemcitabine actavis | Gemcitabine hospira | Gemcitabine Teva | Gemliquid | Gemsol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine | Gemcitabine HCL | Infugem</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabina | Gemcitabina Accord | Gemcitabina actavis | Gemcitabina aurovitas | Gemcitabina Hospira | Gemcitabina Kabi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clorhidrato de gemcitabina blau | Gemcitabina cipla | Gemcitabina gebina | Gemcitabina imedic | Gemcitabina intas | Gemcitabina kemex | Gemcitabina libra | Gemcitabina tuteur</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Citabol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabina Accord | Gemcitabina ebewe | Gemcitabina teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cytogem | Gemcitabin | Gemcitabine | Gemcitabine ebewe | Gemzar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin hospira | Gemcitabin sandoz | Gemcitabin sun | Gemcitabine accord | Gemkabi | Gemzar | Gitrabin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin ebewe | Gemzar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabin Mylan | Gemcitabine kabi | Gemliquid | Gemstad</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine sandoz</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cytogem | Gemsol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Gemful | Gemtu | Gesita</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dbl gemcitabine | Gemcitabine | Gemmis</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Gemcimeda | Gemcitabine accord</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Gemtero</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gemzar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cytigem | Gemcitabine sandoz | Gemita | Spalgem</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Gemcitabine ebewe | Gemtero</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Gemlife | Gemtero</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19841330">
<a name="19841330"></a>Addeo R, Caraglia M, Bellini S, et al. Randomized Phase III Trial on Gemcitabine versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. <i>J Clin Oncol</i>. 2010;28(4):543-548.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19841330/pubmed" id="19841330" target="_blank">19841330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18711184">
<a name="18711184"></a>Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine Plus Paclitaxel versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment. <i>J Clin Oncol</i>. 2008;26(24):3950-3957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/18711184/pubmed" id="18711184" target="_blank">18711184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319238">
<a name="15319238"></a>Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine Combined With Oxaliplatin (GEMOX) in Advanced Biliary Tract Adenocarcinoma: A GERCOR Study. <i>Ann Oncol</i>. 2004;15(9):1339-1343. doi:10.1093/annonc/mdh351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15319238/pubmed" id="15319238" target="_blank">15319238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2016;34(22):2654-2668. doi:10.1200/JCO.2016.67.5561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17426059">
<a name="17426059"></a>Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. <i>Ann Oncol.</i> 2007; 18(6):1071-1079. doi:10.1093/annonc/mdm090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17426059/pubmed" id="17426059" target="_blank">17426059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21947834">
<a name="21947834"></a>Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198. doi:10.1200/JCO.2010.34.4614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21947834/pubmed" id="21947834" target="_blank">21947834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22370319">
<a name="22370319"></a>Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. <i>J Clin Oncol</i>. 2012;30(10):1107-1113. doi:10.1200/JCO.2011.38.6979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/22370319/pubmed" id="22370319" target="_blank">22370319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25964250">
<a name="25964250"></a>Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiosarcoma and gallbladder carcinoma. <i>J Clin Oncol</i>. 2015;33(24):2617‐2622. doi:10.1200/JCO.2014.60.2219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/25964250/pubmed" id="25964250" target="_blank">25964250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18006893">
<a name="18006893"></a>Bokemeyer C, Oechsle K, Honecker F, et al, German Testicular Cancer Study Group. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study group. <i>Ann Oncol.</i> 2008;9(3):448-453. doi:10.1093/annonc/mdm526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/18006893/pubmed" id="18006893" target="_blank">18006893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16271750">
<a name="16271750"></a>Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. <i>Gynecol Oncol</i>. 2006;100(2):385-388. doi:10.1016/j.ygyno.2005.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16271750/pubmed" id="16271750" target="_blank">16271750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10620443">
<a name="10620443"></a>Burnett AF, Roman LD, Garcia AA. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. <i>Gynecol Oncol.</i> 2000;76(1):63-66. doi:10.1006/gyno.1999.5657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10620443/pubmed" id="10620443" target="_blank">10620443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9196156">
<a name="9196156"></a>Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. <i>J Clin Oncol</i>. 1997;15(6):2403-2413. doi:10.1200/JCO.1997.15.6.2403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/9196156/pubmed" id="9196156" target="_blank">9196156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10458212">
<a name="10458212"></a>Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. <i>J Clin Oncol</i>. 1999;17(1):12-18. doi:10.1200/JCO.1999.17.1.12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10458212/pubmed" id="10458212" target="_blank">10458212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7595731">
<a name="7595731"></a>Carmichael J, Possinger K, Phillip P, et al. Advanced Breast Cancer: A Phase II Trial With Gemcitabine. <i>J Clin Oncol</i>. 1995;13(11):2731-2736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/7595731/pubmed" id="7595731" target="_blank">7595731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494637">
<a name="15494637"></a>Cetina L, Rivera L, Candelaria M, de la Garza J, Dueñas-González A. Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. <i>Anticancer Drugs</i>. 2004;15(8):761-766. doi:10.1097/00001813-200409000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15494637/pubmed" id="15494637" target="_blank">15494637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28456635">
<a name="28456635"></a>Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. <i>J Urol</i>. 2017;198(3):552-559. doi:10.1016/j.juro.2017.04.086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/28456635/pubmed" id="28456635" target="_blank">28456635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22748450">
<a name="22748450"></a>Chen C, Wang FH, Wang ZQ, et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. <i>Oral Oncol.</i> 2012;48(11):1146-1151. doi:10.1016/j.oraloncology.2012.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/22748450/pubmed" id="22748450" target="_blank">22748450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33405943">
<a name="33405943"></a>Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. <i>J Clin Oncol</i>. 2021;39(7):840-859. doi:10.1200/JCO.20.03237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/33405943/pubmed" id="33405943" target="_blank">33405943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30122620">
<a name="30122620"></a>Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. <i>Lancet Oncol</i>. 2018;19(9):1229-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/30122620/pubmed" id="30122620" target="_blank">30122620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19224841">
<a name="19224841"></a>Cole PD, Schwartz CL, Drachtman RA, et al. Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report. <i>J Clin Oncol.</i> 2009;27(9):1456-1461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19224841/pubmed" id="19224841" target="_blank">19224841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33278935">
<a name="33278935"></a>Cortes J, Cescon DW, Rugo HS, et al; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i>. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/33278935/pubmed" id="33278935" target="_blank">33278935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35857659">
<a name="35857659"></a>Cortes J, Rugo HS, Cescon DW, et al; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. <i>N Engl J Med</i>. 2022;387(3):217-226. doi:10.1056/NEJMoa2202809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/35857659/pubmed" id="35857659" target="_blank">35857659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15386331">
<a name="15386331"></a>Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). <i>Cancer.</i> 2004;101(8):1835-1842. doi:10.1002/cncr.20587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15386331/pubmed" id="15386331" target="_blank">15386331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12972523">
<a name="12972523"></a>Culine S, Lortholary A, Voigt JJ, et al, Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). <i>J Clin Oncol.</i> 2003;21(18):3479-3482. doi:10.1200/JCO.2003.12.104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/12972523/pubmed" id="12972523" target="_blank">12972523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19858379">
<a name="19858379"></a>Cunningham D, Chau I, Stocken DD, et al. Phase III Randomized Comparison of Gemcitabine versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. <i>J Clin Oncol.</i> 2009;27(33):5513-5518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19858379/pubmed" id="19858379" target="_blank">19858379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24451298">
<a name="24451298"></a>Curtis S, Hong S, Gucalp R, Calvo M. Gemcitabine-induced pseudocellulitis in a patient with recurrent lymphedema: a case report and review of the current literature. <i>Am J Ther</i>. 2016;23(1):e321-e323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/24451298/pubmed" id="24451298" target="_blank">24451298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782913">
<a name="16782913"></a>Dalbagni G, Russo P, Bochner B, et al. Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guerin-Refractory Transitional Cell Carcinoma of the Bladder. <i>J Clin Oncol.</i> 2006;24(18):2729-2734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16782913/pubmed" id="16782913" target="_blank">16782913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12879472">
<a name="12879472"></a>Danson S, Middleton MR, O’Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i>. 2003;98(3):542-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/12879472/pubmed" id="12879472" target="_blank">12879472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16757095">
<a name="16757095"></a>De Giorgi U, Rosti G, Aieta M, et al. Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients With Cisplatin-Refractory Nonseminomatous Germ Cell Tumor. <i>Eur Urol.</i> 2006;50(5):1032-1038. doi:10.1016/j.eururo.2006.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16757095/pubmed" id="16757095" target="_blank">16757095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22162575">
<a name="22162575"></a>De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. <i>J Clin Oncol</i>. 2012;30(2):191-199. doi:10.1200/JCO.2011.37.3571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/22162575/pubmed" id="22162575" target="_blank">22162575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15170150">
<a name="15170150"></a>Delaloge S, Llombart A, Di Palma M, et al. Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study. <i>Am J Clin Oncol</i>. 2004;27(3):289-293. doi:10.1097/01.coc.0000071382.14174.c5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15170150/pubmed" id="15170150" target="_blank">15170150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17385194">
<a name="17385194"></a>Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. <i>Cancer.</i> 2007;109(9):1863-1869. doi:10.1002/cncr.22609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17385194/pubmed" id="17385194" target="_blank">17385194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16131047">
<a name="16131047"></a>Ecklund JW, Trifilio S, Mulcahy MF. Chemotherapy Dosing in the Setting of Liver Dysfunction. <i>Oncology (Williston Park).</i> 2005;19(8):1057-1063.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16131047/pubmed" id="16131047" target="_blank">16131047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10080592">
<a name="10080592"></a>Einhorn LH, Stender MJ, and Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. <i>J Clin Oncol.</i> 1999;17(2):509-511. doi:10.1200/JCO.1999.17.2.509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10080592/pubmed" id="10080592" target="_blank">10080592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of Chemotherapy. <i>Semin Oncol.</i> 2006;33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35403841">
<a name="35403841"></a>Forde PM, Spicer J, Lu S, et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. <i>N Engl J Med</i>. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/35403841/pubmed" id="35403841" target="_blank">35403841</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gemcitabine [prescribing information]. Manalapan, NJ: Armas Pharmaceuticals Inc; January 2020.</div>
</li>
<li>
<div class="reference">
                  Gemcitabine injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; September 2019.</div>
</li>
<li>
<div class="reference">
                  Gemcitabine injection [prescribing information]. Durham, NC: Accord Healthcare; July 2019.</div>
</li>
<li>
<div class="reference">
                  Gemcitabine injection for intravenous infusion [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; April 2018.</div>
</li>
<li>
<div class="reference">
                  Gemzar (gemcitabine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20943374">
<a name="20943374"></a>Geoerger B, Chisholm J, Le Deley MC, et al. Phase II Study of Gemcitabine Combined With Oxaliplatin in Relapsed or Refractory Paediatric Solid Malignancies: An Innovative Therapy for Children With Cancer European Consortium Study. <i>Eur J Cancer.</i> 2011;47(2):230-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20943374/pubmed" id="20943374" target="_blank">20943374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17922972">
<a name="17922972"></a>Greco FA, Spigel DR, Kuzur ME, et al. Paclitaxel/carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. <i>Clin Lung Cancer</i>. 2007;8(8):483-437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17922972/pubmed" id="17922972" target="_blank">17922972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19433683">
<a name="19433683"></a>Grønberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian Lung Cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. <i>J Clin Oncol.</i> 2009;27(19):3217-3224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19433683/pubmed" id="19433683" target="_blank">19433683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22317952">
<a name="22317952"></a>Gross-Goupil M, Fourcade A, Blot E, et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. <i>Eur J Cancer. </i>2012;48(5):721-727. doi:10.1016/j.ejca.2012.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/22317952/pubmed" id="22317952" target="_blank">22317952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20164695">
<a name="20164695"></a>Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. <i>Cancer J</i>. 2010;16(1):70-75. doi:10.1097/PPO.0b013e3181c6aa89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20164695/pubmed" id="20164695" target="_blank">20164695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29578402">
<a name="29578402"></a>Hann A, Nosalski E, Hermann PC, Egger J, Seufferlein T, Keller F. Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review. <i>Clin Nephrol</i>. 2018;90(2):125-141. doi:10.5414/CN109327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/29578402/pubmed" id="29578402" target="_blank">29578402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21572345">
<a name="21572345"></a>Hartmann C, Weinel P, Schmid H, et al. Oxaliplatin, Irinotecan, and Gemcitabine: A Novel Combination in the Therapy of Progressed, Relapsed, or Refractory Tumors in Children. <i>J Pediatr Hematol Oncol.</i> 2011;33(5):344-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21572345/pubmed" id="21572345" target="_blank">21572345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16921047">
<a name="16921047"></a>Heinemann V, Quietzsch D, Gieseler F, et al. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer. <i>J Clin Oncol.</i> 2006;24(24):3946-3952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16921047/pubmed" id="16921047" target="_blank">16921047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18394689">
<a name="18394689"></a>Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. <i>Gynecol Oncol.</i> 2008;109(3):323-328. doi:10.1016/j.ygyno.2008.02.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/18394689/pubmed" id="18394689" target="_blank">18394689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11919245">
<a name="11919245"></a>Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. <i>J Clin Oncol.</i> 2002;20(7):1859-1863. doi:10.1200/JCO.2002.07.158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/11919245/pubmed" id="11919245" target="_blank">11919245</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Infugem (gemcitabine) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327426">
<a name="36327426"></a>Johnson ML, Cho BC, Luft A, et al; POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. <i>J Clin Oncol.</i> Published online November 3, 2022. doi:10.1200/JCO.22.00975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/36327426/pubmed" id="36327426" target="_blank">36327426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37075781">
<a name="37075781"></a>Kelley RK, Ueno M, Yoo C, et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i>. 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/37075781/pubmed" id="37075781" target="_blank">37075781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180816">
<a name="31180816"></a>Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2019;37(23):2082-2088. doi:10.1200/JCO.19.00946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/31180816/pubmed" id="31180816" target="_blank">31180816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12655447">
<a name="12655447"></a>Kiani A, Köhne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. <i>Cancer Chemother Pharmacol</i>. 2003;51(3):266-270. doi:10.1007/s00280-003-0574-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/12655447/pubmed" id="12655447" target="_blank">12655447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29346042">
<a name="29346042"></a>Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical oncology clinical practice guideline. <i>J Clin Oncol</i>. 2018;36(13):1343-1373. doi:10.1200/JCO.2017.76.6394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/29346042/pubmed" id="29346042" target="_blank">29346042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15800324">
<a name="15800324"></a>Knox JJ, Hedley D, Oza A, et al. Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. <i>J Clin Oncol.</i> 2005;23(10):2332-2338. doi:10.1200/JCO.2005.51.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15800324/pubmed" id="15800324" target="_blank">15800324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16344320">
<a name="16344320"></a>Ko AH, Dito E, Schillinger B, et al. Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas. <i>J Clin Oncol.</i> 2006;24(3):379-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16344320/pubmed" id="16344320" target="_blank">16344320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14701772">
<a name="14701772"></a>Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. <i>J Clin Oncol.</i> 2004;22(1):108-114. doi:10.1200/JCO.2004.06.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/14701772/pubmed" id="14701772" target="_blank">14701772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19726456">
<a name="19726456"></a>Koolen SL, Huitema AD, Jansen RS, et al. Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature. <i>Oncologist</i>. 2009;14(9):944-948. doi:10.1634/theoncologist.2009-0111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19726456/pubmed" id="19726456" target="_blank">19726456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11896117">
<a name="11896117"></a>Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. <i>J Clin Oncol</i>. 2002;20(6):1657-1667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/11896117/pubmed" id="11896117" target="_blank">11896117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15117993">
<a name="15117993"></a>Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treatment With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma. <i>J Clin Oncol.</i> 2004;22(9):1706-1712. doi:10.1200/JCO.2004.08.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15117993/pubmed" id="15117993" target="_blank">15117993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31186983">
<a name="31186983"></a>Leung TV, Hughes ME, Cambareri CG, Rubin DJ, Eaby-Sandy B. Systemic treatments for lung cancer patients receiving hemodialysis. <i>J Adv Pract Oncol</i>. 2018;9(6):614-629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/31186983/pubmed" id="31186983" target="_blank">31186983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17309673">
<a name="17309673"></a>Li YF, Fu S, Hu W, et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. <i>Int J Gynecol Cancer</i>. 2007;17(4):739-763. doi:10.1111/j.1525-1438.2007.00847.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17309673/pubmed" id="17309673" target="_blank">17309673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17222747">
<a name="17222747"></a>Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <i>Eur J Cancer</i>. 2007;43(1):14-34. doi:10.1016/j.ejca.2006.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17222747/pubmed" id="17222747" target="_blank">17222747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37290468">
<a name="37290468"></a>Liu LT, Liu H, Huang Y, et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncol</i>. 2023;24(7):798-810. doi:10.1016/S1470-2045(23)00232-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/37290468/pubmed" id="37290468" target="_blank">37290468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14766260">
<a name="14766260"></a>Look KY, Sandler A, Blessing JA, Lucci JA 3rd, Rose PG; Gynecologic Oncology Group (GOG) Study. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. <i>Gynecol Oncol.</i> 2004;92(2):644-647. doi:10.1016/j.ygyno.2003.11.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/14766260/pubmed" id="14766260" target="_blank">14766260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18005385">
<a name="18005385"></a>López A, Gutiérrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. <i>Eur J Haematol.</i> 2008;80(2):127-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/18005385/pubmed" id="18005385" target="_blank">18005385</a>]</span>
<span class="doi">10.1111/j.1600-0609.2007.00996.x</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908661">
<a name="15908661"></a>Louvet C, Labianca R, Hammel P, et al. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. <i>J Clin Oncol.</i> 2005;23(15):3509-3516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15908661/pubmed" id="15908661" target="_blank">15908661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22811861">
<a name="22811861"></a>Lubner S, Hall B, Gopal D, et al. A 37 year-old pregnant woman with pancreatic adeno-carcinoma treated with surgery and adjuvant chemotherapy: a case report and literature review. <i>J Gastrointest Oncol</i>. 2011;2(4):258-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/22811861/pubmed" id="22811861" target="_blank">22811861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34341578">
<a name="34341578"></a>Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nat Med</i>. 2021;27(9):1536-1543. doi:10.1038/s41591-021-01444-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/34341578/pubmed" id="34341578" target="_blank">34341578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17602081">
<a name="17602081"></a>Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002 [published corrections appears in <i>J Clin Oncol</i>. 2007;25(24):3790]. <i>J Clin Oncol.</i> 2007;25(19):2755-2763. doi:10.1200/JCO.2006.10.4117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17602081/pubmed" id="17602081" target="_blank">17602081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12697880">
<a name="12697880"></a>Masters GA, Declerck L, Blanke C, et al; Eastern Cooperative Oncology Group. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. <i>J Clin Oncol.</i> 2003;21(8):1550-1555. doi:10.1200/JCO.2003.09.130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/12697880/pubmed" id="12697880" target="_blank">12697880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2015;33(30):3488-3515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18270381">
<a name="18270381"></a>Masumori N, Kunishima Y, Hirobe M, et al. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. <i>Jpn J Clin Oncol</i>. 2008;38(3):182-185. doi:10.1093/jjco/hym171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/18270381/pubmed" id="18270381" target="_blank">18270381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10663634">
<a name="10663634"></a>Merimsky O, Meller I, Flusser G, et al. Gemcitabine in Soft Tissue or Bone Sarcoma Resistant to Standard Chemotherapy: A Phase II Study. <i>Cancer Chemother Pharmacol.</i> 2000;45(2):177-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10663634/pubmed" id="10663634" target="_blank">10663634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16162979">
<a name="16162979"></a>Mir O, Alexandre J, Ropert S, et al. Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. <i>Anticancer Drugs</i>. 2005;16(9):1017-1021. doi:10.1097/01.cad.0000176503.48433.74<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/16162979/pubmed" id="16162979" target="_blank">16162979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720909">
<a name="19720909"></a>Monk BJ, Sill MW, McMeekin DS, et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. <i>J Clin Oncol.</i> 2009;27(28):4649-4655. doi:10.1200/JCO.2009.21.8909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19720909/pubmed" id="19720909" target="_blank">19720909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17452677">
<a name="17452677"></a>Moore MJ, Goldstein D, Hamm J, et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. <i>J Clin Oncol.</i> 2007;25(15):1960-1966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17452677/pubmed" id="17452677" target="_blank">17452677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19727011">
<a name="19727011"></a>Mora J, Cruz CO, Parareda A, et al. Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel. <i>J Pediatr Hematol Oncol.</i> 2009;31(10):723-729.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19727011/pubmed" id="19727011" target="_blank">19727011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol.</i> 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17602086">
<a name="17602086"></a>Mutch DG, Orlando M, Goss T, et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. <i>J Clin Oncol.</i> 2007;25(19):2811-2818.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17602086/pubmed" id="17602086" target="_blank">17602086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18484657">
<a name="18484657"></a>Navid F, Willert JR, McCarville MB, et al. Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma. <i>Cancer.</i> 2008;113(2):419-425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/18484657/pubmed" id="18484657" target="_blank">18484657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28129987">
<a name="28129987"></a>Neoptolemos JP, Palmer DH, et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet</i>. 2017;389(10073):1011-1024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/28129987/pubmed" id="28129987" target="_blank">28129987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23676600">
<a name="23676600"></a>Nishijima Y, Hirata H, Himeno A, et al. Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin. <i>Intern Med</i>. 2013;52(10):1111-1114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/23676600/pubmed" id="23676600" target="_blank">23676600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12189542">
<a name="12189542"></a>Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. <i>Br J Cancer.</i> 2002;87(5):491-496. doi:10.1038/sj.bjc.6600505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/12189542/pubmed" id="12189542" target="_blank">12189542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24104372">
<a name="24104372"></a>Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. <i>JAMA</i>. 2013;310(14):1473-1481. doi:10.1001/jama.2013.279201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/24104372/pubmed" id="24104372" target="_blank">24104372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17227978">
<a name="17227978"></a>Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. <i>JAMA</i>. 2007;297(3):267-277. doi:10.1001/jama.297.3.267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17227978/pubmed" id="17227978" target="_blank">17227978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oh.1">
<a name="Oh.1"></a>Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. https://evidence.nejm.org/doi/10.1056/EVIDoa2200015. Published online June 1, 2022. Accessed on January 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17437788">
<a name="17437788"></a>Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. <i>J Urol.</i> 2007;177(5):1698-1702. doi:10.1016/j.juro.2007.01.063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17437788/pubmed" id="17437788" target="_blank">17437788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15160509">
<a name="15160509"></a>Ozkaynak MF, Jayabose S. Gemcitabine and Vinorelbine as a Salvage Regimen for Relapse in Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation. <i>Pediatr Hematol Oncol.</i> 2004;21(2):107-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15160509/pubmed" id="15160509" target="_blank">15160509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25471029">
<a name="25471029"></a>Palmieri G, Buonerba C, Ottaviano M, et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. <i>Future Oncol</i>. 2014;10(14):2141-2147. doi:10.2217/fon.14.144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/25471029/pubmed" id="25471029" target="_blank">25471029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19880439">
<a name="19880439"></a>Palmieri G, Merola G, Federico P, et al. Preliminary Results of Phase II Study of Capecitabine and Gemcitabine (CAP-GEM) in Patients With Metastatic Pretreated Thymic Epithelial Tumors (TETs). <i>Ann Oncol.</i> 2010;21(6):1168-1172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19880439/pubmed" id="19880439" target="_blank">19880439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998855">
<a name="14998855"></a>Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and Oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. <i>Ann Oncol.</i> 2004;15(3):493-497. doi:10.1093/annonc/mdh103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/14998855/pubmed" id="14998855" target="_blank">14998855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15839957">
<a name="15839957"></a>Pfisterer J, Vergote I, Du Bois A, et al. Combination Therapy with Gemcitabine and Carboplatin in Recurrent Ovarian Cancer. <i>Int J Gynecol Cancer.</i> 2005;15(suppl 1):36-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15839957/pubmed" id="15839957" target="_blank">15839957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19581537">
<a name="19581537"></a>Poplin E, Feng Y, Berlin J, et al. Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (Fixed-Dose Rate Infusion) Compared With Gemcitabine (30-Minute Infusion) in Patients With Pancreatic Carcinoma E6201: a Trial of the Eastern Cooperative Oncology Group. <i>J Clin Oncol.</i> 2009;27(23):3778-3785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19581537/pubmed" id="19581537" target="_blank">19581537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15022294">
<a name="15022294"></a>Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. <i>Cancer.</i> 2004;100(6):1257-1261. doi:10.1002/cncr.20100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15022294/pubmed" id="15022294" target="_blank">15022294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15741225">
<a name="15741225"></a>Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. <i>Ann Oncol</i>. 2005;16(4):602-610. doi:10.1093/annonc/mdi126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15741225/pubmed" id="15741225" target="_blank">15741225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15197207">
<a name="15197207"></a>Reid JM, Qu W, Safgren SL, et al. Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors. <i>J Clin Oncol.</i> 2004;22(12):2445-2451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15197207/pubmed" id="15197207" target="_blank">15197207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20555089">
<a name="20555089"></a>Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20555089/pubmed" id="20555089" target="_blank">20555089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10623702">
<a name="10623702"></a>Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. <i>J Clin Oncol</i>. 2000;18(1):122-130. doi:10.1200/JCO.2000.18.1.122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10623702/pubmed" id="10623702" target="_blank">10623702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17229633">
<a name="17229633"></a>Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. <i>Haematologica.</i> 2007;92(1):35-41. doi:10.3324/haematol.10661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17229633/pubmed" id="17229633" target="_blank">17229633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15589587">
<a name="15589587"></a>Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. <i>Gynecol Oncol.</i> 2005;96(1):103-107. doi:10.1016/j.ygyno.2004.09.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/15589587/pubmed" id="15589587" target="_blank">15589587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates.<i> Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30856044">
<a name="30856044"></a>Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(12):1015‐1027. doi:10.1200/JCO.18.02178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/30856044/pubmed" id="30856044" target="_blank">30856044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32755482">
<a name="32755482"></a>Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online August 5, 2020. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21072518">
<a name="21072518"></a>Suyanı E, Sucak GT, Akı ŞZ, et al. Gemcitabine and Vinorelbine Combination Is Effective in Both as a Salvage and Mobilization Regimen in Relapsed or Refractory Hodgkin Lymphoma Prior to ASCT. <i>Ann Hematol.</i> 2011;90(6):685-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/21072518/pubmed" id="21072518" target="_blank">21072518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12885837">
<a name="12885837"></a>Tempero M, Plunkett W, Ruiz Van Haperen V. Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma. <i>J Clin Oncol. </i>2003;21(18):3402-3408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/12885837/pubmed" id="12885837" target="_blank">12885837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22936563">
<a name="22936563"></a>Tanji N, Fukumoto T, Miura N, et al. Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency. <i>Int J Clin Oncol</i>. 2013;18(5):910-915. doi:10.1007/s10147-012-0466-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/22936563/pubmed" id="22936563" target="_blank">22936563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20375404">
<a name="20375404"></a>Valle J, Wason H, Palmer DH, et al. Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer. <i>N Engl J Med.</i> 2010;362(14):1273-1281. doi:10.1056/NEJMoa0908721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/20375404/pubmed" id="20375404" target="_blank">20375404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11875695">
<a name="11875695"></a>van Haarst JM, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. <i>Br J Cancer.</i> 2002;86(3):342-345. doi:10.1038/sj.bjc.6600118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/11875695/pubmed" id="11875695" target="_blank">11875695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10375105">
<a name="10375105"></a>van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Cancer</i>. 1999;85(12):2577-2582. doi:10.1002/(sici)1097-0142(19990615)85:12&lt;2577::aid-cncr13&gt;3.3.co;2-j<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10375105/pubmed" id="10375105" target="_blank">10375105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10894879">
<a name="10894879"></a>Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.<i> J Clin Oncol</i>. 2000;18(14):2780-2787. doi:10.1200/JCO.2000.18.14.2780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10894879/pubmed" id="10894879" target="_blank">10894879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11001674">
<a name="11001674"></a>von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. <i>J Clin Oncol.</i> 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/11001674/pubmed" id="11001674" target="_blank">11001674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24131140">
<a name="24131140"></a>Von Hoff DD, Ervin TJ, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <i>N Engl J Med</i>. 2013;369(18):1691-1703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/24131140/pubmed" id="24131140" target="_blank">24131140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25032054">
<a name="25032054"></a>Wiesweg M, Aydin S, Koeninger A, et al. Administration of gemcitabine for metastatic adenocarcinoma during pregnancy: a case report and review of the literature. <i>AJP Rep</i>. 2014;4(1):17-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/25032054/pubmed" id="25032054" target="_blank">25032054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10467815">
<a name="10467815"></a>Xu Q, Zhang Y, Trissel LA. Physical and chemical stability of gemcitabine hydrochloride solutions. <i>J Am Pharm Assoc (Wash)</i>. 1999;39(4):509-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/10467815/pubmed" id="10467815" target="_blank">10467815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T. Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17909810">
<a name="17909810"></a>Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. <i>Cancer Chemother Pharmacol.</i> 2008;61(1):33-38. doi:10.1007/s00280-007-0441-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17909810/pubmed" id="17909810" target="_blank">17909810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35709465">
<a name="35709465"></a>Zhang Y, Chen L, Hu GQ, et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. <i>J Clin Oncol</i>. 2022;40(22):2420-2425. doi:10.1200/JCO.22.00327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/35709465/pubmed" id="35709465" target="_blank">35709465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31150573">
<a name="31150573"></a>Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma.<i> N Engl J Med</i>. 2019;381(12):1124-1135. doi:10.1056/NEJMoa1905287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/31150573/pubmed" id="31150573" target="_blank">31150573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17613425">
<a name="17613425"></a>Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. <i>Lancet Oncol.</i> 2007;8(7):634-641.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gemcitabine-pediatric-drug-information/abstract-text/17613425/pubmed" id="17613425" target="_blank">17613425</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13154 Version 462.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
